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Background 
Cystationine β-synthase (CBS) deficiency is a genetic disorder characterized by severe hyperhomocysteinemia 
and thrombotic complications. In healthy individuals, physical exercise may result in a transient increase in 
plasma total homocysteine (tHcy) raising the possibility that exercise might be detrimental in CBS deficiency. 
Our main objective was to determine plasma tHcy kinetics in response to physical exercise in homocystinuria 
patients. 
Methods 
Six adult patients (2 males, 4 females) with homocystinuria and 6 age- and gender-matched controls 
completed a 30-min aerobic exercise of moderate-intensity with fixed power output (50 W for women and 100 W 
for men). Blood samples were drawn before, immediately, 180 min and 24 h after exercise. tHcy levels were 
determined by standard procedures; substrate oxidation and energy expenditure were measured using indirect 
calorimetry. 
Results 
Acute exercise was well tolerated and safe in patients and controls. During the exercise bout, heart rate and 
energy expenditure increased equally in both groups. tHcy levels were higher in patients compared to controls at 
all time points (p < 0.05). There was no significant effect of exercise on tHcy levels at any time point (p = 0.36). 
Although two patients with partial pyridoxine responsiveness presented higher homocysteine responses, their 
highest value remained below 55 μmol/l. 
Conclusions 
Overall metabolic responses to acute exercise were similar between homocystinuria patients and controls; 
specifically, exercise did not significantly change tHcy concentrations. Moderate physical exercise was well 
tolerated without any adverse event in our cohort of patients. Further studies are needed to identify the effects of 
different intensities and modes of exercise in larger cohorts of CBS patients with different levels of pyridoxine 
responsiveness.   
1. Introduction
Cystathionine beta-synthase (CBS) deficiency, also known as clas-
sical homocystinuria (OMIM# 236200), is a rare inherited autosomal 
recessive disorder affecting methionine transsulfuration. The charac-
teristic biochemical pattern consists of severely elevated plasma 
homocysteine (Hcy) and methionine and low-normal to reduced 
cysteine [1]. Hcy is a non-proteogenic amino acid produced in the liver 
from dietary methionine. CBS, a pyridoxine (vitamin B6)-dependent 
enzyme, catalyzes the condensation of homocysteine with serine to form 
cystathionine, a precursor of cysteine. CBS deficiency impairs homo-
cysteine conversion leading to plasma hyperhomocysteinemia [2]. CBS 
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deficiency occurs worldwide with variable prevalence across countries 
depending on ethnicity and a wide range of age at presentation. Clinical 
symptoms are variable affecting the ocular, musculoskeletal, vascular 
and central nervous systems [3]. Thromboembolism is the major cause 
of early death and morbidity [2]. Patients with pyridoxine- 
responsiveness have usually a milder phenotype [4,5]. 
In the general population, plasma Hcy is associated with an increased 
risk of venous and arterial thrombosis, cardiovascular and all-cause 
mortality [6–8]. Although plasma concentrations in this population 
are 10-folds lower than in untreated CBS deficient patients, these phe-
nomena have been explained by impairment of vascular endothelial 
function [9,10], increase in oxidative stress, and impaired peripheral 
vasomotor response [11]. Thus, Hcy has been proposed as an indepen-
dent cardiovascular risk factor [6,7,12,13], where each increase of 5 
μmol/l in plasma homocysteine level increases the risk of coronary heart 
disease (CHD) events by approximately 20% independently from other 
CHD risk factors [14]. While regular exercise is recommended in in-
dividuals with CHD risk factors [15], the impact of physical activity on 
Hcy remains unclear. Some studies show a transient increase of Hcy 
during and/or after acute exercise in healthy subjects, other show no 
clear relationship between Hcy kinetics and exercise [16–18]. 
Although these findings suggesting that physical exercise results in 
increased plasma Hcy in the general population are controversial, they 
raise an important question in our clinics: could a bout of exercise be 
detrimental to patients with homocystinuria? There is currently no in-
formation on the effect of acute exercise on total Hcy levels in CBS 
deficient individuals. Consequently, recommendations are lacking in 
regards to exercise safety, duration, intensity and frequency in this 
specific population. The aim of this study was to 1) assess whether one 
acute bout of moderate-intensity exercise would increase Hcy in CBS 
deficient patients compared to healthy controls, 2) ascertain exercise 
safety and tolerance in CBS deficient patients and 3) evaluate metabolic 
adaptations using indirect calorimetry and plasma amino acid 
measurements. 
2. Methods
2.1. Subjects and study design
Patients were recruited from the outpatient clinic of the Adult 
Metabolic Clinic, Division of genetic medicine at the Lausanne Univer-
sity Hospital (CHUV). To be included they had to be over 18 years of age 
with genetically confirmed CBS deficiency. For each patient, an age- and 
gender-matched healthy control was recruited. Exclusion criteria for all 
participants comprised any clinically unstable condition, any contrain-
dication to moderate exercise, blood sampling or a recent participation 
in another clinical study. Patients were also excluded if their total 
plasmatic homocysteine (tHcy) concentration at the screening visit was 
above 100 μmol/l and above 20 μmol/l for controls. The study design 
consisted in one screening visit followed after inclusion by a pre− /post- 
acute exercise intervention comparison consisting in two visits (Fig. S1). 
Patients were required to continue their regular treatment and diet 
throughout the duration of the study. 
The study protocol was approved by the ethics committee of the 
Canton of Vaud (Protocol# 2018-02400). All patients provided written 
informed consent for participation in this study. All procedures followed 
were in accordance with the ethical standards of the responsible com-
mittee on human experimentation and with the Helsinki Declaration of 
1975, as revised in 2000. This trial was registered at the U.S Clinical 
Trials Registry as NCT04021732. 
2.2. Screening visit (visit 1)
Participants were invited to the screening visit after an overnight fast 
at their habitual outpatient clinic. After signing the informed consent, 
the visit comprised the medical interview, clinical examination and 
blood sampling to assess tHcy, vitamin B9 and B12. After estimating 
daily caloric requirements based on the Harris-Benedict equation, a 
trained dietician implemented an individualized isoenergetic diet 
including 1.2 g/kg/day of proteins. Participants were instructed to 
follow this diet for 3 days, starting 24 h before visit 2. To evaluate energy 
and protein intake, a 5 days food record was requested starting 3 days 
before visit 2. Participants were also instructed to refrain from any 
structured exercise for 7 days prior to visit 2 and abstain from 
consuming caffeine, tobacco and any drugs. 
2.3. Exercise visit (visit 2) and follow up (visit 3)
On the day of visit 2, participants arrived to the clinical physiology 
lab (Plateau Technique de Physiologie Humaine) at 8:00 AM following a 
12-h overnight fast. Upon arrival, weight was measured on a calibrated 
medical digital scale (Seca, Hamburg, Germany) in light clothes without 
shoes. Vital signs were collected after 10 min resting in the supine po-
sition. Compliance with the dietary and behavioral instructions 
described above was assessed and participants were asked to rest in bed 
without any stimuli for 30 min. This was followed by the resting 
metabolic evaluation with indirect calorimetry as specified below. A 
venous catheter was inserted into a forearm vein for repeated blood 
sampling. The pre-exercise blood sample was drawn (T0) and was fol-
lowed by the 30-min exercise protocol described below. Immediately 
after the exercise bout, a blood sample was collected (T1). While 
recovering in the supine position under close surveillance a third blood 
sample was collected at +180 min since the start of the exercise bout 
(T2). After this time point, the participant was fed and discharged. 
On the following day, participants referred to the outpatient clinic 
after an overnight fast. A clinical interview was performed to assess 
potential complications and all dietary records were collected. A last 
blood sample was taken at exactly +24 h since the start of the acute 
exercise bout (T3). A follow up call was performed 1-week post-exercise 
for a final check-up. 
2.4. Resting metabolic rate and heart rate
Indirect calorimetry was performed using an open canopy system 
(Quark, Cosmed, Rome, Italy). Subjects were placed under the canopy 
while resting in bed in a thermally neutral environment. This was 
combined with resting heart rate (HR) recording using an integrated 
fingertip pulse meter (ipod, Nonin Medical Inc., Plymouth, MN). Sub-
jects were told to close their eyes and try to sleep, refrain from fidgeting, 
and not to perform any type of activity (i.e., watching TV or reading). 
The duration of the test was between 30 min to assure a minimal steady 
state of 20 min with the first 10 min of data discarded. Oxygen con-
sumption (V̇O2) and carbon dioxide production (V̇CO2) were recorded 
every 10 s (Omnia software, Cosmed) and used for the computation of 
respiratory exchange ratio (RER=V̇CO2/V̇O2) also known as respiratory 
quotient at rest. Resting energy expenditure (EE) was calculated using 
Weir’s equation: REE = [(3.9 × V̇O2) + (1.1 × V̇CO2)] [19]. Systemic 
rate of fat oxidation (Fat-ox) and carbohydrate oxidation (CHO-ox) were 
computed as previously described [20]. Protein oxidation rates were not 
measured based on the assumption that the amount of protein oxidized 
are quantitatively negligible compared to glucose and fatty acid oxida-
tion [21]. 
2.5. Exercise protocol
The exercise test consisted of a constant 30-min submaximal effort on 
a calibrated electronically braked cycle ergometer (Excalibur; Lode B.V., 
Groningen, The Netherlands). For safety reasons, given that no previous 
data exist on the effect of acute exercise in CBS patient’s, we decided to 
avoid maximal exercise testing and chose to use a single-stage fixed 
intensity submaximal exercise test with power output based on gender 
and fitness status as suggested from the American College of Sports 
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Medicine guidelines for exercise testing [15]. Given that all patients and 
controls were non-athletic, the chosen submaximal fixed power outputs 
were 100 W for men and 50 W for women. V̇CO2 and V̇O2 were 
measured breath-by-breath by indirect calorimetry (CPET, Cosmed, 
Rome, Italy) using fitted facemasks. Metabolic computations included 
exercise EE, RER, Fat-ox and CHO-ox as described above. Metabolic 
equivalents (MET) were used to compute relative exercise intensity 
taking into account each individual’s V̇O2 and body weight [15]. HR was 
measured continuously with a wireless monitor (ANT+, Garmin Canada 
Inc., Cochrane, Canada). Rate of perceived exertion (RPE) was ascer-
tained each 5 min with the Borg scale [22]. Both HR and RER were 
closely monitored to remain within the limits of moderate intensity 
exercise defined as a HR range between 55 and 70% of the computed 
maximal HR and a RER < 1.1. Participants were instructed to share any 
discomfort experienced during the exercise test. Exercise would have 
been discontinued in case of HR above 85% of maximal HR, RER > 1.1, 
chest discomfort, breath shortness, sudden fatigue, nauseas or light- 
headedness. None of the patients or controls required an early termi-
nation, thus all volunteers completed the exercise protocol. 
2.6. Biological analysis and genotyping
Total plasma homocysteine (tHcy) was measured on a Zorbax Eclipse 
XDB-C18 column (Agilent) on an Acquity UPLC™ system (Waters, 
Milford, USA). Free plasma amino acids were measured by LCMS using 
an Acquity UPLC H-Class system (Waters, USA). Molecular studies of 
CBS gene were done by Next Generation Sequencing (NGS; Ion S5, 
Themofisher) and results confirmed by bidirectional fluorescent direct 
sequencing (Sanger Sequencing; 3500 Genetic Analyzer, Thermofisher). 
2.7. Data management and statistical analyses
Unless specified, data are expressed as mean ± SEM. Statistical an-
alyses and figures were done using Prism version 8 for MacOs (GraphPad 
Software LLC, San Diego, CA). Comparisons between groups were tested 
with the non-parametric Kolmogorov-Smirnov test. Repeated measures 
two-way ANOVA with the Geisser-Greenhouse correction were used to 
assess tHcy and amino acids differences across groups (2 levels for the 
between factor) and time points (4 levels for the within factor). Post hoc 
analyses were performed using the Tukey’s HSD method to control for 
multiple comparisons. Repeated measures two-way ANOVA with the 
Geisser-Greenhouse correction were used to assess metabolic adapta-
tions between groups (2 levels for the between factor) and two condi-
tions (at rest and during exercise, 2 levels for the within factor). Post hoc 
analyses were performed using the Sidak correction for multiple com-
parisons. Associations were assessed using Spearman’s rank-order cor-
relation. Two tailed tests were used for all analyses. The statistical 
significance level was set at 0.05. 
3. Results
3.1. Subjects characteristics
Six patients with confirmed homocystinuria were recruited in this 
study, 4 females and 2 males. Genetic diagnostics, screening visit tHcy, 
classification of pyridoxine (B6) responsiveness according to the Euro-
pean network and registry for homocystinurias and methylation defects 
(E-HOD registry) [23] and clinical presentation are indicated in Table 1. 
Two patients (P1 and P5) were B6 partial responders while the other 
patients were extreme (P2) or full responders (P3, P4 and P6). 
All patients were on daily oral vitamin B6 (doses ranging from 40 to 
300 mg/day) and vitamin B9 (0.4 to 7.5 mg/day). B6 partial responders 
(P1 and P5) were also treated with oral Betaine (respectively 12 and 8 g/ 
day) as well as methionine-free L-amino acid mixture (respectively 120 
and 90 g/day, containing 84 and 63 g of protein) and a methionine- 
restricted diet. 
Per design, age and gender were not different between patients and 
controls. Patients had on average higher tHcy than controls (Table 1). 
3.2. Kinetic of plasma homocysteine with exercise
At each time point, tHcy levels were higher in patients compared to 
controls with non-parametric comparisons (Fig. 1A; all p < 0.05). When 
analyzing the two groups across time points (2 × 4 repeated measures 
ANOVA), having the disease accounted for 28.3% of the total variance 
after adjusting for the matched design (p = 0.07). There was no signif-
icant effect of time (p = 0.36) and no interaction effect (p = 0.45). In-
dividual responses to the acute bout of exercise are presented in Fig. 1B. 
Although the time point with a larger modification from T0 was T2, as 
witnessed by the larger Y axis scale in Fig. 1D, no significant differences 
were evidenced at any of the time points. Strong associations were 
present between T0 and all post exercise points (Fig. 1G–I). The strength 
of these correlations was explained by the patient’s results. 
Important individual tHcy variations were observed for the two pa-
tients with partial B6 responsiveness (P1 and P5). P1 tHcy went from 
36.4 μmol/l at T0, to 38.6 at T1, 50.5 at T2 and 35 at T3. P5 tHcy went 
from 13.3 μmol/l at T0, to 18 at T1, 51.6 at T2 and finally 20.6 at T3. 
Thus for these two patients, percent changes between the lower and the 
higher tHcy concentrations were respectively 39% and 288% (Fig. 1F). 
Importantly at each time point, tHcy level remained close to the target 
limit for treated patients (< 50 μmol/l). 
Another interesting observation was made for a fully vitamin B6 
responsive patient (P3) who had a screening visit tHcy of 35.3 μmol/l. 
This patient’s tHcy levels were high to start with and remained in the 
same range across the four time points (111.7, 114.7, 115.5 and 119.2 
μmol/l). Very probably, would the experimenters not be blinded at that 
time of the day, the exercise test would have been cancelled. Indeed, for 
methodological reasons although each sample was processed and 
centrifuged immediately after each blood drawn; chromatography was 
done overnight and the results were available on the next day. A pos-
teriori, no explanation was obtained to explain such an elevated tHcy in 
this patient who was followed with frequent visits afterwards. 
3.3. Tolerance to exercise and metabolic adaptations
RPE was similar in patients and controls (Fig. 2A). Exercise intensity 
was within the submaximal target and similar in both groups as wit-
nessed by MET (Fig. 2B). HR and EE increased with exercise equally in 
both groups (Fig. 2C–E). Respiratory exchange ratios reflected expected 
adaptations for submaximal exercise intensity without significant dif-
ferences between groups (Fig. 2F). From rest to moderate exercise, the 
contribution of energy source shifted as expected with a reduction of 
energy from fat oxidation. Both groups responded to the exercise stim-
ulus but with a higher difference in patients than controls explaining the 
significant interaction (Fig. 2G). 
Plasmatic concentrations of the different amino acids involved in 
CBS and creatine metabolism (ornithine, glycine, arginine and methio-
nine) as well as branched-chain amino acids (leucine, isoleucine and 
valine) were not significantly different across groups or time points 
(supplementary Table S1). This was comparable to a previous study with 
healthy volunteers [24]. 
When analyzing the percent change differences in methionine be-
tween baseline and all post exercise time points, we observed that two 
patients were explaining the large variability in this group, these were 
the two patients with partial B6 responsiveness (P1 and P5). As an 
illustration of this point, if we take the difference between T0 and T3, 
which is the larger percent change in methionine, this was on average 
− 3.428 ± 8.188% in patients and − 8.629 ± 2.111% in controls (p =
0.56). All participants had values ranging from − 3.846 to − 21.849%, 
while the change for P1 was of +3.625% and P5 of +32.653%. 
Protein intake, including formula and medical food, was significantly 
lower in patients than controls when expressed relative to body weight 
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M 21 74.6 45.4 588 PR Y N N Y N Y Y Y
P2 CBS c.341C>T hom F 26 9 45.4 426 ER Y N N N N N Y N
P3 CBS c.502G>T/
c.770C>T
F 25 35.3 45.4 1476 FR Y N N N Y Y Y N
P4 CBS c.502G>T/
c.770C>T
F 28 18.1 45.4 616 FR Y N N N N N Y N
P5 CBS c.19dup/
c.805_807del
M 26 28.9 45.4 1091 PR Y N N Y N Y Y Y
P6 CBS c.833T>C hom F 50 21.2 35.5 469 FR Y N Y N Y N N N
Median 4F/
2M
26.0 25.05 45.40 602.0 6Y 6N 1Y/5N 2Y/4N 2Y/4N 3Y/3N 5Y/1N 2Y/4N
Mean 29.3 31.18 43.75 777.7
(±SD) (10.4) (23.11) (4.04) (416.4)
C7 Ctrl M 22 9.8 20.4 438 NA N N N N N N N N
C8 Ctrl F 25 9.5 16 271 NA N N N N N N N N
C9 Ctrl F 23 7.8 20.7 262 NA N N N N N N N N
C10 Ctrl F 32 14.4 7.3 389 NA N N N N N N N N
C11 Ctrl M 25 11.7 18.5 347 NA N N N N N N N N
C12 Ctrl F 49 12.4 14.5 778 NA N N N N N N N N
Median 4F/
2M
25.0 10.75 17.25 368.0 6N 6N 6N 6N 6N 6N 6N 6N
Mean 29.3 10.93 16.23 414.2
(±SD) (10.3) (2.36) (5.01) (190.7)
Group comparison exact p-value  0.896 0.026 0.002 0.143
Abbreviations: CBS, cystathionine-β synthase; Ctrl: control; CV: cardio-vascular; del: deletion; dup: duplication; ER: extreme B6 responsiveness; F: female; hom: homozygous; FR: full B6 responsiveness; M: man; mmHg: 
millimeter of mercury; N: no; NA: not applicable; PR: partial B6 responsiveness, tHcy: total plasmatic homocysteine, Y: yes. 
a For vitamin B9, measurement upper limit was >45.4 pmol/l. 
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(0.95 g/d/kg and 1.30 g/d/kg of body weight respectively) (Fig. 3A–B). 
Overall energy intake was similar in both groups with lower recorded 
daily consumptions compared to the nutritional requirements 
(Fig. 3C–D). 
4. Discussion
To the best of our knowledge, this is the first study to evaluate ex-
ercise safety in CBS patients. To do so, we analyzed patient’s tHcy 
response to a controlled moderate-intensity aerobic exercise bout with a 
24-h follow up. We observed 1) that exercise did not change significantly 
Fig. 1. Total homocysteine response to acute exercise. 
(A) Group tHcy kinetics across time points (mean and SEM). (B) Individual tHcy across time points. (C-E) Percent change from baseline. Each group median is 
represented by a straight line. (F) Patients (P#) variability at the maximal change. (G-I) Correlations between baseline and each time point across all subjects. 
Magnifications correspond to the control group. ρ is the Spearman’s correlation coefficient. For all panels, open circles are patients, crosses are controls, *p < 0.05. 
tHcy is total homocysteine. 
A.T. Tankeu et al.                                                                                                                                                                                                                              
Molecular Genetics and Metabolism Reports 27 (2021) 100746
6
tHcy concentrations in CBS patients and controls matched by age and 
gender, 2) that one bout of 30 min exercise was well tolerated and safe in 
CBS patients and 3) that metabolic responses to exercise were similar 
between CBS patients and controls. However, our results point to a 
potential specificity of two patients with partial B6 responsiveness in 
which the response to exercise seemed different from the other CBS 
patients with full responsiveness. 
An important factor to consider is that we did not perform a maximal 
exercise testing in each subject to allow the prescription of relative ex-
ercise intensity to each person’s physical condition. Indeed, this was not 
possible given that no previous data was available to ascertain safety in 
these patients. Nevertheless, the results of energy expenditure and 
metabolic equivalents measured during the acute exercise bout prove 
that with the chosen fixed submaximal power outputs, similar exercise 
intensities were reached in both groups and across genders. 
Our results were measured in all CBS patients followed in the 
Fig. 2. Exercise tolerance and metabolic adaptations. 
(A) Mean rate of perceived exercise (RPE) during the exercise bout. (B) Mean metabolic equivalents (MET) during the exercise bout. (C) Mean heart rate at rest and 
during the exercise bout. (D-E) Energy expenditure (EE) in absolute units and relative to body weight (BW) at rest and during the exercise bout. (F) Respiratory 
exchange ratios at rest and during the exercise bout. (G) Relative fat and carbohydrate (Carb) oxidation at rest and during the exercise bout. Open circles are patients, 
crosses (A-F) or crossed circles (G) are controls. Bars are mean, error bars are SEM, #significant interaction, *significant effect of time, 1 symbol p < 0.05, 3 symbols 
p < 0.0001. 
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Division of Genetic Medicine who fulfilled the inclusion criteria. The 
small sample size is a limitation in this study, thus making comparisons 
between subgroups of patients not possible. Importantly our data sug-
gests individual variations and also the fact that the magnitude of 
change in tHcy after exercise does not depend on baseline values since 
the patient with the highest tHcy showed almost no variation after ex-
ercise and the patient that showed the greatest variations was within 
target concentrations of tHcy. 
The genotype of patient 1 is known to be associated with partial B6 
responsiveness [25], while that of patient 5 suggests complete loss of 
function and thus probably also associated with limited response to B6. 
Indeed, patient 1 and patient 5 were the ones with the highest increase 
in tHcy elevation from baseline to 180 min post exercise. Further, these 
two patients were the only ones presenting positive methionine percent 
changes post-exercise. This raises the question of a genotype-phenotype 
relationship with regard to the effect of exercise on Hcy levels as well as 
the mechanisms driving this effect. 
The exact mechanism by which acute exercise affects Hcy concen-
trations is unknown. Findings in intervention studies remain contro-
versial with works showing increases in Hcy and others showing 
decreases or no effects, in different study populations or exercise pro-
tocols [18,24,26–28]. Among the hypotheses explored to explain the 
impact of acute exercise on Hcy, previous authors have suggested an 
accelerated protein catabolism [29], increases in methionine leading to 
an increased methionine transsulfuration [30], an increased demand for 
creatine synthesis which requires methylated substrates [31], a higher 
production of free radicals influencing thiol-disulfide exchange and thiol 
redox reactions [32] and finally an increased cellular export of the 
reduced form of Hcy which is exported to the extracellular space when 
the remethylation and transsulfuration pathways are inefficient or 
saturated [27]. In our study methionine levels, branched-chain amino 
acids and also amino acids involved in the pathways of creatine (argi-
nine, ornithine and glycine) remained unchanged after 30 min of 
moderate intensity aerobic exercise. 
In the current clinical management guidelines for CBS patients, there 
are no recommendations in terms of habitual physical activity and ex-
ercise prescription [1,2]. Given the multitude of epidemiological studies 
in the general population pointing to the relationship between levels of 
Hcy and cardiovascular events [6,7,12], as well as to the increase of 
tHcy after acute exercise [16–18], more studies are needed to under-
stand the long-term effects of exercise as well as different exercise in-
tensities and modes in CBS patients. 
In addition to homocysteinemia, CBS patients may present with 
other medical complications, such as body habitus (i.e., dolichosteo-
melia), osteoporosis, various bone deformities and/or ophthalmological 
complications (i.e., ectopia lentis) [1]. Furthermore, for patients with 
history of hypercoagulability, a special attention should be brought to 
the possible transient effect of exercise in increasing the hypercoagula-
ble state. As for all individuals with disabilities or specific health con-
ditions, exercise prescription for CBS patient’s should be planned 
individually, addressing (1) the patient’s phenotype, compliance with 
treatment, and usual homocysteine levels, and (2) the type and intensity 
Fig. 3. Nutritional adherence measured during the 3-days preceding the exercise test. 
(A–B) Total protein intake (natural protein and methionine-free L-amino acid mixture) in absolute units and relative to body weight. (C–D) Energy intake re-
quirements and consumption in absolute units and relative to body weight. Circles are patients, crosses are controls. Bars are mean, error bars are SEM, *p < 0.05. 
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of exercise, particularly those sports that may increase intravascular 
pressure, the risk of traumatic lens dislocation and/or fracture. 
5. Conclusion
In summary, our study shows that an acute bout of moderate aerobic 
exercise was safe and well tolerated in our cohort of CBS patients and 
had no significant impact on tHcy concentrations. Future studies are 
needed to confirm exercise safety and tolerance in a larger number of 
patients as well as to evaluate the impact of gender, B6-responsiveness, 
genotype and underlying treatments in tHcy response to exercise. We 
hope that these observations will confirm that physical activity can be 
encouraged in CBS patients and considered in further CBS guidelines. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ymgmr.2021.100746. 
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